Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100534Source: DataRank Database

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis is a research paper published in JTO Clinical and Research Reports (2023). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.12)OA: goldTopics (17)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Lesli A. Kiedrowski ORCID,Rebecca S. Heist ORCID,W. Marston Linehan ORCID,Catherine B. Meador ORCID,Elizabeth Krueger

Live enrichment

PubMed:37533439 OpenAlex:https://openalex.org/W4379052616

National Institutes of Health

Grant: R37 CA225655

National Institutes of Health

Grant: 5R01 CA164273

National Cancer Institute

Grant: K12CA087723-16

FWCI

2.12

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.jtocrr.org/article/S2666364323000735/pdf

publisherhttp://www.jtocrr.org/article/S2666364323000735/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666364323000735?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364323000735?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtocrr.2023.100534

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms

Keywords

CrizotinibAlectinibMedicineLung cancerInternal medicineAnaplastic lymphoma kinaseTolerabilityOncologyALK inhibitorCommon Terminology Criteria for Adverse EventsGastroenterologyCeritinibCancerAdverse effect

Sustainable Development Goals

SDG 0: Good health and well-being